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In tro duc ti on
Hypophosphatasia (HPP) is a rare inherited disorder
characterized by defective bone and tooth mineralization,
together with low serum and bone alkaline phosphatase
(ALP) activity (1). The incidence of the severe form is
estimated to be 1/100 000. However, mild forms may be
more common (2,3). The symptoms are highly variable in
their clinical expression, which range from stillbirth with no
mineralized bone to premature teeth loss alone (1). Six
forms of the disease are identified according to age at
diagnosis and severity of symptoms. These clinical forms
are: perinatal lethal, prenatal benign, infantile, childhood,
adult forms, and odontohypophosphatasia. The
transmission of severe forms is autosomal recessive, while
milder forms may be transmitted as dominant or recessive
autosomal traits (3). The diagnosis is based on clinical and
radiological findings of bone demineralization in the face of
a low serum ALP level. Molecular analysis of the 
tissue-nonspecific (i.e. liver/bone/kidney) ALP (TNALP) gene
can verify the genetic defect (4). 
Patients with the infantile form may appear normal at
birth; however, clinical signs appear within the first 6
months of life (3). Patients may present with respiratory
complications due to rachitic deformities of the chest,
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premature craniosynostosis that may result in increased
intracranial pressure (IICP), hypercalcemia and its
symptoms such as irritability, poor feeding, anorexia,
vomiting, polydypsia, polyuria, dehydration, constipation,
hypotonia and, less commonly, seizures. 
Here, we present the clinical and biochemical findings
as well as the molecular analysis of a case of infantile HPP
associated with hypercalcemia, pyridoxine-responsive
seizures (West syndrome) and pseudotumor cerebri.
Case Report
A 4-month-old boy was admitted to our clinic for
hypercalcemia and seizures refractory to treatment. He
was the fifth child of parents who were first cousins. He
was born at 36 weeks’ gestation after an uneventful
pregnancy. Delivery was spontaneous via the vaginal route.
His birth weight was 3000 g. He was discharged from the
hospital on the second postnatal day, but was readmitted
to the same hospital on the next day with hypotonia, poor
feeding, and generalized tonic-clonic seizures. The
patient’s electroencephalogram (EEG) revealed epileptic
activity in the left frontal area. He was started on
phenobarbital (PB) and phenytoin (DPH), which controlled
his tonic-clonic seizures. However, the myoclonic
convulsions as well as bouts of crying and screaming
continued. An EEG taken at age 2 months showed
hypsarrhythmia. Synacthen and valproic acid were started,
but 2 days later, the baby developed involuntary
movements of the extremities and was found to have
hypercalcemia. At this time, DPH and valproic acid as well
as synacthen were discontinued, and in the following days,
the patient received only PB. Later, clonazepam was added
to the treatment regimen, but the involuntary movements of
the extremities continued until 4 months of age when he
was referred to our center. 
Physical examination at the time of admission revealed
short stature (length 55 cm, <3rd percentile). Weight was also
below the 3rd percentile for age (4400 g). Generalised muscle
hypotonia, a bulging anterior fontanelle, short and bowed
lower extremities (Figure 1), and a simian crease in the left
palm were noted. There were no physical signs of rachitic
changes in the chest.  X-rays showed mineralization defect
in the long bones, cupping of the metaphyses, and defective
ossification in the skull bones (Figure 2A,B,C). The chest X-
rays showed no abnormalities (Figure 2D). Blood chemistry
findings were: total calcium 14.6 mg/dL (N:8.5-10.5); ionized
calcium 1.6 mmol/L (N: 1.14-1.29); phosphorus 4.81 mg/dL
(N:3.5-5.5);  ALP 7 IU/L (N: 150-240), parathyroid hormone
(PTH) <3 pg/mL (N:12-95), 25-hydroxyvitamin D [25(OH)D]
32.7 ng/mL (N:10-60), magnesium 1.68 mg/dL (N: 1.4-1.9).
Repeat ALP level was also remarkably low (11 IU/L)
suggesting HPP when considered together with the clinical
and radiological findings of mineralization defect. Urinary
calcium/creatinine ratio was 1.37. Urinary
phosphoethanolamine excretion was elevated (172.4
μmol/L; N:0-10) supporting the diagnosis of HPP. Other
markers of bone turnover were also elevated (urinary
deoxypyridinoline 157.4 nMDPD/mMcre, N:2.3-5.4; serum
osteocalcine 64.7 ng/mL, N:9.9-27).  Serum electrolytes,
glucose, blood gases, hepatic and renal function tests as
well as routine urinalysis were all within normal limits. Renal
ultrasonography revealed medullary hyperechogenicity
suggesting medullary nephrocalcinosis. Cranial magnetic
resonance (MR) imaging showed mild ventricular dilatation.
Further laboratory investigation directed to the etiology of
seizures included tandem mass spectrometry, urinary and
plasma amino acid analysis, urinary organic acid analysis,
visual evoked potential (VEP) and brain auditory evoked
potential (BAEP) studies, as well as electroretinography
(ERG), and all were within normal limits.       
Fi gu re  1. (A) bulging of anterior fontanelle,  and (B) hypotonic, short and
bowed extremities of  the patient
Fi gu re  2(A,B,C,D). X-rays show bowing and angulation in the long bones,
defective mineralization in the epiphyses and metaphyses, demineraliza-
tion in the skull, and a normal chest X-ray
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D CIntravenous (IV) hydration with saline plus furosemide
was started at the time of admission to treat
hypercalcemia, and dietary calcium intake was restricted.
This therapy had minimal effect on calcium levels and
serum calcium was 13.8 mg/dL on the 3rd hospital day. The
hypercalcemia was resistant to other treatment options
including prednisolone (2 mg/kg/d) and calcitonin (10
U/kg/d). Normocalcemia was achieved with a single dose
of 0.5 mg/kg IV pamidronate.
A lumbar puncture (LP) was performed to investigate
the cause of the bulging anterior fontanelle. Opening
pressure was increased (270 cm H2O). Cerebrospinal fluid
(CSF) glucose and protein levels were all within normal
limits, and cultures were negative. Absence of any organic
lesion on MR imaging as well as the normal CSF findings in
the face of IICP suggested pseudotumor cerebri. No
additional therapy was recommended since the patient did
not have symptoms of IICP such as vomiting or irritability.
A follow-up LP was also not performed since there was no
change in the patient’s clinical condition suggestive of
either resolution or progression of pseudotumor cerebri.  
The patient was on PB and clonazepam at the time of
admission, but his seizures (involuntary twitching)
continued despite this treatment. Pyridoxine was tried on
the second day after his admission when a diagnosis of
HPP was considered. Seizures refractory to previous
antiepileptic therapy resolved completely following
pyridoxine administration (100 mg/day initial and 50
mg/day maintenance dose, PO). A follow-up EEG, carried
out 6 days after the initial dose of pyridoxine, showed
voltage suppression but no epileptiform anomaly. The
patient was discharged after resolution of hypercalcemia
and seizures. Further molecular analysis performed at the
S.E.S.E.P laboratory in France confirmed the diagnosis of
HPP. A homozygous c.659G>C (p.G220A) missense
mutation was found on exon 7. The parents were
heterozygous for the mutation.
The patient was lost to follow-up after discharge. He
was followed by a local university close to his residence.
Unfortunately, we learned that he had died at the age of 8
months in the course of pulmonary infection.
Discussion 
HPP is a rare disorder among the various causes of
hypercalcemia. On the other hand, hypercalcemia is
frequent in HPP patients, particularly in those with the
infantile form of the disease (5,6,7). Hypercalcemia is
thought to be due to impaired bone mineralization in the
presence of normal bone resorption. TNALP deficiency
impairs bone mineralization by inhibition of the growth of
hydroxyapatite crystals caused by increased inorganic
pyrophosphate (PPi) which is a substrate for the defective
enzyme. 
There is some controversy in the literature about the
preferred treatment for hypercalcemia in patients with HPP.
Dietary restriction of calcium intake is recommended in
most papers. On the other hand, there is much conflict
about the use or harmful effects of saline solution,
furosemide, chlorothiazide, glucocorticoids, calcitonin and
bisphosphonates (pamidronate) (5,6,7). The conflict arises
from a number of reasons. Firstly, since this is a rare
disorder, information about the treatment and effect of the
treatment on hypercalcemia is based on reports of single
cases. Secondly, the disease has a tendency to improve
with age even in the severe forms, thus, it is not unusual
that a report suggests sudden resolution of hypercalcemia
which may coincide with some form of conventional
treatment for hypocalcemia. Thirdly, probably there is
some individual variation with regard to bone formation and
resorption among these patients. Osteoclasts are generally
accepted to function normally and lead to age-appropriate
bone resorption in patients with HPP. In parallel with this
information, markers of bone resorption (i.e. pyridinoline,
deoxypyridinoline) are within normal limits in most case
reports, however, there are also patients in whom bone
resorption is increased, as demonstrated by the presence
of the same markers, which would be expected to influence
the response to treatment. All in all, therapies directed at
improving hypercalcemia are expected to worsen bone
demineralization. Bisphosphonates are not expected to be
effective in treating hypercalcemia in patients with HPP
since bone resorption is normal in this condition. Despite
this knowledge, since other treatments had not been
effective to normalize serum calcium and also because
urinary deoxypyridinoline was elevated, suggesting
increased resorption, a single dose of pamidronate was
tried in our patient and was found to  successfully decrease
the serum calcium level to the high-normal range. We also
found that this effect could be sustained by continuing
glucocorticoid therapy and by calcium restriction.
Unfortunately, the patient succumbed because of
pulmonary infection at the age of 8 months.
Pyridoxine-responsive seizures have been reported in
association with HPP, and in fact, they are considered to
be an indicator of disease severity (8,9,10,11). Several
specific mutations have been suggested to be responsible
(8,9,10,11,12). A very similar case has been reported by
Baumgartner-Sigl et al. previously (8). That case presented
with pyridoxine-responsive seizures as a neonate and
developed skeletal demineralization, hypercalcemia,
hypercalciuria and nephrocalcinosis consistent with HPP
later in infancy.
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The mechanism of pyridoxine-responsive seizures in
HPP is explained by defective metabolism of pyridoxal 
5-phosphate (PLP), which is the phosphorylated form of
pyridoxine (vitamin B6). TNALP hydrolyses PLP, and the
unphosphorylated pyridoxine crosses the blood-brain
barrier to be re-generated as PLP (13). PLP is a co-enzyme
for glutamic acid decarboxylase, which plays a crucial role
in the synthesis of gamma-aminobutyric acid (GABA) (10).
The inability of defective TNALP to cleave PLP may result
in vitamin B6 deficiency, thus reducing the levels of
inhibitory neurotransmitter GABA in the brain leading to
seizures (14). Studies of ALP activity in the primate brain
support the important role of this enzyme in
neurotransmission. Kinetic characterization of TNALP
mutations showed that some mutations were efficient in
hydrolysing PPi but inefficient in hydrolysing PLP, which
could explain why some patients manifest more severe
seizures than others (15,16,17).
In the current case, we observed IICP as well, initially
suggested by a bulging fontanelle and later documented by
an elevated CSF pressure. MR imaging excluded organic
lesions as the cause of IICP, suggesting pseudotumor
cerebri. Pseudotumor cerebri may arise from abnormalities
in serum calcium levels in hypo- or hypercalcemia (18).
Teber et al (19) previously reported a case of HPP who had
pseudotumor cerebri which resolved after glucocorticoid
therapy. They suggested that, as found in their patient,
pseudotumor cerebri could be ascribed to hypercalcemia
and resolved after correction of the hypercalcemia with
glucocorticoid therapy.
Alternatively, premature closure of sutures is held
responsible for IICP in patients with HPP. Craniosynostosis
is a well-known feature of the infantile and childhood HPP.
Collmann et al (20) reported a series of 7 children among 20
cases of HPP who had craniosynostosis and discussed the
functional problems arising from HPP. In our patient, cranial
sutures and anterior fontanelle were wide open, thus,
craniosynostosis cannot be held responsible for the IICP.
The molecular defect detected in our case was
previously reported in 2 cases with severe perinatal HPP
(21). Interestingly, in one of those cases, the patient was
homozygous for the mutation c.659G>C and the parents
were first cousins of Turkish origin. In the second case, the
patient was a compound heterozygote with c.659G>C and
another defect, and the parent carrying the c.659G>C
mutation was again of Turkish origin. These findings
strongly suggest a founder effect of this mutation in Turkey.
The mutation affects an amino acid that is not located in
the functional 3D domain of the TNALP protein. However,
the residue G220 is highly conserved during evolution and
another mutation affecting the same residue (c.659G>T,
p.G220V) is also responsible for HPP (22), corroborating
the disease-causing role of the mutation.
In conclusion, HPP is a rare cause of hypercalcemia in
childhood and should be suspected when serum ALP is
found to be low. In some cases, HPP may be associated
with pyridoxine-responsive seizures. Pseudotumor cerebri
may also develop in some cases. The current patient had
all of these clinical features. In addition, it is noteworthy
that the mutation described in this patient was shown in 2
other non-related Turkish families as well, a finding which
suggests a founder effect of this mutation in Turkey.
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